Transcriptional Enhancer Factor Domain Family member 4 Exerts an Oncogenic Role in Hepatocellular Carcinoma by Hippo‐Independent Regulation of Heat Shock Protein 70 Family Members

Mairene Coto‐Llerena, Nadia Tosti, Stephanie Taha‐Mehlitz, Venkatesh Kancherla, Viola Paradiso, John Gallon, Gaia Bianco, Andrea Garofoli, Souvik Ghosh, Fengyuan Tang, Caner Ercan, Gerhard M. Christofori, Matthias S. Matter, Raoul A. Droeser, Mihaela Zavolan, Savas D. Soysal, Markus Flüe, Otto Kollmar, Luigi M. Terracciano, Charlotte K. Y.

Metabolic Profiling of Bile Acids in the Urine of Patients with Alcohol‐Associated Liver Disease

Liqing He, Vatsalya Vatsalya, Xipeng Ma, Jiayang Zhang, Xinmin Yin, Seongho Kim, Wenke Feng, Craig J. McClain, Xiang Zhang – 19 January 2021 – Bile acids (BAs) play important functions in the development of alcohol‐associated liver disease (ALD). In the current study, urine BA concentrations in 38 patients with well‐described alcohol‐associated hepatitis (AH) as characterized by Model for End‐Stage Liver Disease (MELD), 8 patients with alcohol‐use disorder (AUD), and 19 healthy controls (HCs) were analyzed using liquid chromatography–mass spectrometry.

SOMAscan Proteomics Identifies Serum Biomarkers Associated With Liver Fibrosis in Patients With NASH

Yi Luo, Samir Wadhawan, Alex Greenfield, Benjamin E. Decato, Abdul M. Oseini, Rebecca Collen, Diane E. Shevell, John Thompson, Gabor Jarai, Edgar D. Charles, Arun J. Sanyal – 19 January 2021 – Nonalcoholic steatohepatitis (NASH) is a major cause of liver‐related morbidity and mortality worldwide. Liver fibrosis stage, a key component of NASH, has been linked to the risk of mortality and liver‐related clinical outcomes.

Trials & Tribulations of Liver Transplantation‐ are trials now prohibitive without surrogate endpoints?

James Richards, Alex Gimson, Yexin Joh, Christopher J.E. Watson, James Neuberger – 18 January 2021 – During the past 5 decades, liver transplantation has moved from its pioneering days where success was measured in days to a point where it is viewed as a routine part of medical care. Despite this progress, there are still significant unmet needs and outstanding questions that need addressing in clinical trials to improve outcomes for patients.

Subscribe to